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Abstract
Background: The development of an effective vaccine against visceral leishmaniasis (VL) caused by Leishmania 
donovani is an essential aim for controlling the disease. Use of the right adjuvant is of fundamental importance in 
vaccine formulations for generation of effective cell-mediated immune response. Earlier we reported the protective 
efficacy of cationic liposome-associated L. donovani promastigote antigens (LAg) against experimental VL. The aim of 
the present study was to compare the effectiveness of two very promising adjuvants, Bacille Calmette-Guerin (BCG) 
and Monophosphoryl lipid A (MPL) plus trehalose dicorynomycolate (TDM) with cationic liposomes, in combination 
with LAg, to confer protection against murine VL.
Results: All the three formulations afforded significant protection against L. donovani in both the visceral organs, liver 
and spleen. Although comparable level of protection was observed in BCG+LAg and MPL-TDM+LAg immunized mice, 
highest level of protection was exhibited by the liposomal LAg immunized group. Significant increase in anti-LAg IgG 
levels were detected in both MPL-TDM+LAg and liposomal LAg immunized animals with higher levels of IgG2a than 
IgG1. But BCG+LAg failed to induce any antibody response. As an index of cell-mediated immunity DTH responses 
were measured and significant response was observed in mice vaccinated with all the three different formulations. 
However, highest responses were observed with liposomal vaccine immunization. Comparative evaluation of IFN-γ 
and IL-4 responses in immunized mice revealed that MPL-TDM+LAg group produced the highest level of IFN-γ but 
lowest IL-4 level, while BCG+LAg demonstrated generation of suboptimum levels of both IFN-γ and IL-4 response. 
Elicitation of moderate levels of prechallenge IFN-γ along with optimum IL-4 corresponds with successful vaccination 
with liposomal LAg.
Conclusion: This comparative study reveals greater effectiveness of the liposomal vaccine for protection against 
progressive VL in BALB/c. Again, evaluation of the immune responses by vaccination emphasizes the need of 
stimulation of potent cellular immunity based on both Th1 and Th2 cell responses to confer protection against VL.
Background
Leishmaniases are a wide spectrum of diseases caused by
trypanosomatid parasites of the genus Leishmania with
two million new cases of human infection worldwide
each year [1]. The clinico-pathological categories range
from self-healing cutaneous lesions to visceral leishmani-
asis (VL), the latter being an invariably fatal disease in the
absence of drug treatment. Currently available chemo-
therapeutic agents are usually associated with high cost
and toxicity [2]. Moreover, the emergence of drug resis-
tance has raised an urgent demand for development of a
safe and effective vaccine to combat the disease.
Recently, a great deal of effort has been directed
towards generation of subunit vaccines that may be safer
than whole cell vaccines [3]. A major limiting factor for
the development of subunit vaccines is the appropriate
adjuvant to enhance and tailor the effective and long last-
ing immune response. Bacille Calmette-Guerin (BCG)
and Monophosphoryl lipid A (MPL) are two immunos-
timulatory adjuvants that act directly on the immune sys-
tem to augment cell-mediated response to the associated
antigens. BCG, in addition to being the most widely used
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Page 2 of 10vaccine in the world since 1921, is an immune-modulator
stimulating several Toll-like receptors (TLRs) that can
potentiate Th1 biased immune response [4-6]. BCG alone
can protect mice against leishmaniasis [7,8], and it has
also long been used as an adjuvant in field efficacy trials
of candidate vaccines against leishmaniasis [9]. MPL, the
non-toxic derivative of the lipopolysaccharide (LPS) of
Salmonella minnesota is a safe and well-tolerated adju-
vant approved for human use. It signals via TLR4 for the
activation of T-cell effector response. Several immuniza-
tion trials including Leishmania, malaria, human papillo-
mavirus (HPV), Hepatitis B virus (HBV), tuberculosis
and HIV with different formulations of MPL have estab-
lished the safety and efficacy of this promising adjuvant
[10]. Cationic liposomes are lipid-bilayer vesicles with a
positive surface charge that have emerged as a promising
new adjuvant technology having low toxicity and biode-
gradability. They are very effective antigen-deliver sys-
tems and serve to markedly enhance the uptake and
presentation of antigens by antigen presenting cells.
Thus, they potentiate cell-mediated and humoral
immune response to poorly immunogenic protein and
peptide antigens [11-14] and generate solid and durable
immunity against experimental VL [15-18].
Investigations of immune protection mechanisms
against leishmaniasis reveals that a shift in the balance
from interleukin (IL)-4 to interferon (IFN)-γ provides the
key to vaccine success in cutaneous leishmaniasis (CL)
[19]. Protective immunity in VL also correlates with a
Th1 and IFN- γ production [20]. But immune response to
VL is a more complex reaction where an exclusive gener-
ation of a vaccine-induced Th1 is insufficient to ensure
protection, and cannot predict vaccine success [21,22].
Although induction of IL-4 in infected BALB/c and non-
curing models has been reported [23,24], beneficial roles
of IL-4 have also been described for L. donovani infection
[25,26].
Our earlier studies showed that leishmanial antigens
(LAg) entrapped in cationic liposomes induced protec-
tion against progressive models of VL [15]. With the aim
of improving vaccine formulation against this disease
potential human-compatible adjuvants, BCG and MPL,
were selected for combination with LAg. Thus, in the
present study the protective efficacy of LAg with BCG
and MPL-TDM were evaluated and compared with LAg
entrapped in cationic liposomes when given by same
intraperitoneal route against experimental challenge of L.
donovani in BALB/c mice. A comparative evaluation of
the immune responses elicited by the three different vac-
cine formulations was investigated to understand the
immune mechanisms responsible for the differences in
their protective abilities.
Results
Comparison of parasite burden in differently adjuvanted 
LAg vaccinated mice after L. donovani challenge infection
To compare the efficacy of vaccination against VL with
LAg in three different adjuvants, BALB/c mice were
immunized intraperitoneally with BCG + LAg, MPL-
TDM+LAg and LAg entrapped in cationic liposomes.
The vaccination was repeated twice at 2-week intervals
and the mice were challenged intravenously with L. dono-
vani promastigotes 10 days after the last immunization.
Control mice received PBS or adjuvants alone. After 2
and 4 months of challenge infection clearance of hepatic
and splenic parasite burden was monitored. The parasite
loads were quantitated as LDU in liver and spleen biop-
sies. As shown in Figure 1 control mice receiving PBS or
adjuvants alone developed highest parasite load in the
liver and spleen as an outcome of progressive disease
[15,16,27,28]. In liver, immunization with BCG + LAg
and MPL-TDM + LAg did not result in any protection at
2 months post-infection (Figure 1A). However, there was
significant and comparable level of decrease in parasite
load in both the groups, suggesting a specific partial pro-
tection after 4 months of challenge infection as compared
with PBS and corresponding free adjuvant immunized
groups (P < 0.001). Interestingly, mice immunized with
liposomal LAg showed highest reduction in parasite load
in liver after 2 as well as 4 months of challenge which is
significantly lower than BCG+LAg and MPL-TDM+LAg
vaccinated groups (P < 0.001).
In BALB/c mice persistence of L. donovani in the
spleen causes concomitant development of considerable
organ-specific pathology similar to that seen in the
human kala-azar. It was, therefore, important to evaluate
the effect of vaccination in this organ. Similar to liver,
mice immunized with BCG+LAg and MPL-TDM+LAg
demonstrated partial and comparable level of protection
in spleen after 4 months challenge (Figure 1B; P < 0.01,
compared to controls). However, liposomal LAg immuni-
zation exhibited the maximum level of reduction in
splenic parasite load at both 2 and 4 months after chal-
lenge (P < 0.001, compared to controls).
Antigen-specific humoral responses in differently 
adjuvanted LAg vaccinated mice
To evaluate the humoral immune responses induced by
three differently adjuvanted vaccine formulations, the
serum levels of leishmanial antigen-specific IgG and its
isotypes, IgG1 and IgG2a, from all the vaccinated groups
were assessed by ELISA. Following immunization, IgG as
well as IgG1 and IgG2a were elevated in all LAg adju-
vanted immunized groups, except BCG+LAg, in which
they remained at background levels of control groups
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found in MPL-TDM+LAg immunized mice over the con-
trol groups (P < 0.05); however, the levels were low com-
pared with liposomal LAg immunized group (P < 0.05).
Importantly, the level of IgG2a was higher than that of
IgG1 in both MPL-TDM+LAg and liposomal LAg immu-
nized mice. With progressive infection, significant
increase in total IgG was detected in all the immunized
groups that became comparable to controls after 4
months of challenge infection (Figure 2B and 2C).
Increased levels of IgG2a were still maintained in MPL-
TDM+LAg and liposomal LAg immunized groups com-
pared to control groups (P < 0.01).
Stimulation of DTH response in differently adjuvanted LAg 
vaccinated mice
As an index of parasite antigen specific cell mediated
response in vivo, DTH response was measured in vacci-
nated mice 10 days after last immunization and recalled
at 2 and 4 months after challenge infection. Vaccinated
mice with free LAg and its combination with different
adjuvants displayed significant DTH response in compar-
ison to control groups (Figure 3; P < 0.05). However, the
response by both BCG and MPL-TDM adjuvanted LAg
was comparable but lower than the response induced by
liposomal LAg immunization (P < 0.01). With challenge
infection the response was increased progressively in LAg
and its adjuvanted immunized groups and showed that
the levels were significantly higher compared to the con-
trol groups at 2 and 4 months post-infection (P < 0.05).
Among the differently adjuvanted groups, BCG+LAg and
MPL-TDM+LAg immunized mice exhibited comparable
levels of response whereas higher response was induced
by the liposomal LAg immunized group (P < 0.05) at all
time points after challenge infection.
Generation of IFN-γ and IL-4 response in differently 
adjuvanted LAg vaccinated mice
Although BCG+LAg failed to induce serological response
after immunization, the response was enhanced with
infection and become comparable with other groups.
Conversely, BCG+LAg and MPL-TDM+LAg immuniza-
tion induced and maintained comparable level of cell-
mediated immune response with challenge infection
which led to protection in both the groups. Thus investi-
gation of detailed vaccine induced cell-mediated
response after immunization may help to understand the
underlying mechanism of different formulations that can
correlate with the observed protection. Next, we evalu-
ated the Th1 and Th2 cytokine responses in differently
adjuvanted mice. Splenocytes from immunized mice
were isolated 10 days after immunization and, IFN-γ and
IL-4 levels were measured in vitro following restimula-
tion with LAg. LAg in different adjuvant vaccinated
groups produced substantial amounts of IFN-γ compared
to controls (Figure 4A; P < 0.001). Interestingly, the most
pronounced increase in IFN-γ level was observed in
MPL-TDM+ LAg vaccinated groups in comparison to
Figure 1 Evaluation of protection against L. donovani in differently adjuvanted LAg vaccinated mice . Kinetics of liver (A) and spleen (B) para-
site burden of mice immunized intraperitoneally three times at 2-week intervals with BCG-LAg, MPL-TDM+LAg and LAg entrapped in cationic lipo-
somes. Control animals received PBS or adjuvant only. At 10 days after the last immunization, mice were challenged intravenously with 2 × 107 
promastigotes of L. donovani. At the designated times mice were sacrificed and LDU were calculated from the weight and microscopic examination 
of impression smears of liver and spleen tissues. Each bar represents the mean ± SE for five individual mice per group. The results are those from one 
experiment representative of two performed. Asterisks over each bar indicate significant differences in comparison to control groups. Asterisks over 
line indicate significant differences between groups. *, P < 0.05; **, P < 0.01; ***, P < 0.001; ns, not significant.
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BCG+LAg secreted lower amount of IFN-γ compared
with the liposomal LAg immunized group (P < 0.05).
Mice receiving BCG+LAg and liposomal LAg immuniza-
tion showed significant increase in IL-4 production com-
pared to controls (Figure 4B, P < 0.001). However,
elicitation of significantly higher IL-4 response was
observed in liposomal LAg vaccinated mice compared to
BCG+LAg immunized groups (P < 0.01). In contrast to
the robust IFN-γ responses observed with MPL-
TDM+LAg vaccine, IL-4 level was significantly lower
from other vaccinated groups (P < 0.01). Thus, MPL-
TDM+LAg triggered highest IFN-γ but lowest IL-4 indi-
cating an exclusive Th1 cell-mediated immune response.
BCG+LAg and liposomal LAg generated a mixed Th1/
Th2 response as evident from significant production of
both IFN-γ and IL-4 post-immunization groups. But
compared to the Th1/Th2 response generated by lipo-
somal LAg, the cytokine levels were lower for BCG+LAg
immunized groups.
Discussion
Despite the current knowledge of immunology and
pathology related to the parasite Leishmania, till now, a
desirable vaccine for humans has not been successfully
developed. The main goal of vaccination is the induction
of a protective immune response against the pathogen.
Successful vaccination strategies for Leishmania have
relied on presentation of antigen with appropriate adju-
vants to the host immune system to stimulate effective
Figure 2 Specific antibody responses in differently adjuvanted 
LAg vaccinated mice . Mice were immunized three times at 2-week 
intervals. Ten days after immunization mice were challenged with L. 
donovani. Serum samples were collected after the last booster (A) and 
2 (B) and 4 months (C) after infection and assayed for LAg specific IgG 
and its isotypes IgG1 and IgG2a antibodies by ELISA. Each sample was 
examined in duplicate. Each bar represents the mean absorbance val-
ues at 450 nm ± SE of five individual mice per group at designated time 
points. The results are those from one experiment representative of 
two performed. Asterisks over each bar indicate significant differences 
in comparison to control groups. *, P < 0.05; **, P < 0.01; ***, P < 0.001.
Figure 3 DTH responses in differently adjuvanted LAg vaccinated 
mice . Mice were immunized three times at 2-week intervals. Ten days 
after immunization mice were challenged with L. donovani. After the 
last immunization and 2 and 4 months after infection LAg-specific DTH 
responses were measured. The response is expressed as the difference 
(in mm) between the thickness of the test (LAg-injected) and control 
(PBS-injected) footpads at 24 h. Each bar represents the mean ± SE for 
five individual mice per group at designated time points. The results 
are those from one experiment representative of two performed. As-
terisks over each bar indicate significant differences in comparison to 
control groups. Asterisks over line indicate significant differences be-
tween groups. *, P < 0.05; **, P < 0.01; ***, P < 0.001; ns, not significant.
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the first direct, head-to-head comparison of vaccine for-
mulations using three different adjuvants, BCG, MPL-
TDM and cationic liposomes, with the same leishmanial
antigen for their efficacy against L. donovani challenge in
BALB/c model.
BCG and MPL were chosen as adjuvants in this study as
they are human-compatible potent inducer of cell-medi-
ated immunity. BCG, being almost the only adjuvant
licensed for human use and effective against intracellular
pathogen infections, was extensively used in clinical trials
of vaccination against CL and VL [9]. Amongst the adju-
vants recently approved for human vaccines is MPL, a
potent stimulator of Th1 response, being evaluated in
clinical trials against various diseases including malaria,
tuberculosis and leishmaniasis [10]. Previous studies
from our laboratory established that cationic liposomes is
a potent adjuvant as they have the ability to enhance pro-
tective cell-mediated immune response against experi-
mental VL [15-18]. Thus, cationic liposomes was selected
to compare its efficacy with two other human-compatible
adjuvants BCG and MPL to confer protection against L.
donovani infection.
Comparison of the vaccine potentiality of cationic lipo-
somal formulation of LAg with BCG+LAg and MPL-
TDM+LAg revealed that all the three vaccines afforded
significant protection against challenge with L. donovani.
However, cationic liposome was the most potent of the
three adjuvants and conferred protection superior to
other two adjuvants. The ability of cationic liposomes to
induce significant protection with LAg is entirely consis-
tent with results of our previous studies in mice as well as
hamster models of VL [15]. However, the level of protec-
tion afforded by this formulation was lower than mice
immunized with SLA (soluble leishmanial antigens)
entrapped in these vesicles or LAg entrapped in neutral
and cationic DSPC liposomes [16,27,29], suggesting
entrapment of more immunogenic antigens or optimiza-
tion of liposomal formulation could influence the efficacy
of cationic liposomes. Cationic liposomes was also shown
to be a potent adjuvant to enhance immune response
against CL [30]. BCG is the most widely used adjuvant in
clinical vaccine trials against leishmaniasis including VL.
Although the vaccines were found to be safe and immu-
nogenic, the efficacy was not carried over to a protective
effect [31,32]. Reports on the ability of BCG-vaccine to
protect against leishmaniasis even in experimental mod-
els vary from effective [33,34] to partial protection
[35,36]. MPL-SE (stable emulsion) has been found to be
safe and efficacious against cutaneous and mucosal leish-
maniasis in mice, non-human primates and humans
when vaccinated with Leishmania-derived recombinant
polyprotein Leish-111f or its component proteins [37-
39]. In experimental model of VL, MPL-SE formulated
Leish-111f was effective in reducing splenic parasite bur-
den [37] whereas recombinant sterol 24-c-methyltrans-
ferase (rSMT) plus MPL-SE afforded significant
protection in both liver and spleen [40]. Furthermore,
although MPL formulated 78 kDa antigen of L. donovani
was efficacious in liver against challenged with L. dono-
vani infection [41], partial protection was observed with
Leishmania antigen in association with MPL-Dimethyl
Figure 4 IFN-γ and IL-4 responses in differently adjuvanted LAg vaccinated mice . Mice were immunized three times at 2-week intervals. Ten 
days after last immunization spleens were collected from mice and restimulated in vitro with LAg (10 μg/ml). After 72 h supernatants were collected 
and concentrations of released IFN-γ (A) and IL-4 (B) levels were determined by ELISA. Each sample was examined in duplicate. Each bar represents 
the mean ± SE for five individual mice per group. The results are those from one experiment representative of two performed. Asterisks over each bar 
indicate significant differences in comparison to control groups. Asterisks over line indicate significant differences between groups. *, P < 0.05; **, P < 
0.01; ***, P < 0.001.
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organ where parasites persist and are more resistant to
various immunological interventions and even T cell-
dependent chemotherapy.
Serological data show that mice vaccinated with MPL-
TDM+LAg and liposomal LAg induced strong humoral
responses after immunization that persisted after chal-
lenge infection. Conversely and in accordance to previous
reports [33,34], mice vaccinated with BCG-LAg failed to
respond with the production of antibodies prior to infec-
tion. BCG is known to stimulate APCs through several
TLRs as well as to activate and recruit NK cells and neu-
trophil granulocytes. However, it could not act as a depot
for coadministered antigens for generation of antibody
response [43].
Successful vaccination for the control of parasite multi-
plication is often related to antigen induced DTH
response as an indication of activation of cell-mediated
response. In the present study, results obtained upon vac-
cination with LAg in association with BCG, MPL-TDM
and liposomes demonstrated induction of an appreciable
DTH response suggesting the activation of cell-mediated
immunity. The induction of DTH was, however, highest
in mice immunized with liposomal LAg with lower and
comparable levels induced by BCG+LAg and MPL-TDM
+ LAg. In clinical trials injection of BCG mixed with
killed parasites significantly increased cell-mediated
immune responses to the vaccine was measured by leish-
manin skin test (LST). The LST conversion due to vacci-
nation corresponded with reduced incidence of infection
at least in the subpopulation of "responders" to vaccina-
tion [32]. Animals successfully vaccinated with BCG and
leishmanial antigens similarly elicited DTH reactions
[33,34]. Significant elevation of DTH response in mice
immunized with protein antigens and MPL-DDA that
provided resistance against VL has also been reported
[42]. The significantly higher DTH response induced by
liposomal LAg over BCG+LAg and MPL-TDM+LAg
before and after challenge infection demonstrates elicita-
tion of strong and persistent cell-mediated immunity by
this vaccine, which resulted in greater resistance against
disease.
An important leishmanicidal effector mechanism is the
production of IFN-γ by Leishmania-specific cells, which
in turn activates macrophages to kill intracellular para-
sites. Immunization of BALB/c mice with BCG, MPL-
TDM and liposomal LAg resulted in high IFN-γ produc-
tion following in vitro restimulation. The levels of IFN-γ,
however, varied in the three vaccination groups. Moder-
ate levels of IFN-γ were produced by liposomal vaccine
followed by BCG+LAg vaccine. In contrast, robust levels
of IFN-γ were observed with MPL-TDM+LAg vaccine.
Interestingly, whereas immunization with liposomal as
well as BCG+LAg also led to very significant, though
variable, levels of IL-4 production, the level of IL-4 by
MPL-TDM+LAg vaccine was low. A Th1 phenotypic
response was thus elicited by MPL-TDM+LAg whereas
liposomal and BCG+LAg elicited a mixed Th1/Th2
response. IFN-γ, a signature cytokine of Th1 response is
associated with resistance against L. major. But high IFN-
γ production cannot be the sole criterion that might con-
fer protection against L. donovani [19]. Moreover, in con-
trast to CL, early IL-4 production is not detrimental and
may have a protective role in VL [16-18,25,27]. The role
of IL-4 in conferring protection against L. donovani is
also supported from a finding where chemotherapy
against VL in IL-4 -/- mice is not effective [26]. Thus, the
optimum levels of both the cytokines IFN-γ and IL-4
induced by the liposomal LAg vaccination substantiate
earlier observations that a mixed Th1/Th2 response is
essential for protection against VL [16-18,27,44]. Hence,
we believe that the inability of MPL-TDM to stimulate
optimal IL-4, as observed with the liposomal vaccine for-
mulation, is probably the major factor for its partial suc-
cess in protection. The low immunogenecity of
BCG+LAg characterized by sub-optimal antigen-specific
IFN-γ and IL-4 responses may be responsible for the low
level of protection induced by this vaccine.
In order to compare the protective efficacy of BCG and
MPL-TDM with liposome, all the three vaccine formula-
tions were administered through the intraperitoneal
route. In contrast to liposomes, the success or failure of
protection with BCG+LAg and MPL-TDM+LAg was
probably not dependent on the route of immunization.
Although, intradermal route of immunization is favoured
for BCG formulations, intraperitoneal vaccination of
BCG with a combination of dehydroepiandrosterone
peptide has been reported for the successful prevention
of asthma development [45]. Again, subcutaneous
administration of MPL vaccine has been found to be suc-
cessful for vaccinination against leishmaniasis [37]. Fur-
ther, immunization of MPL-TDM in association with an
immunogenic peptide administered either through sub-
cutaneous or intraperitoneal routes was found to induce
the same Th1-biased response [46]. Conversely, adminis-
tration of liposomal LAg through subcutaneous route
failed to induce protection in experimental mice model of
VL [47]. When the intraperitoneal route is used, perito-
neal macrophages are the major population of APCs
available. It has been found that induction of the immune
response by liposomal delivery of antigen is mainly mac-
rophage dependent and DCs are considered to be less
efficient in phagocytosis than cells of the macrophage lin-
eage [48]. Thus intraperitoneal immunization of lipo-
somal antigen could effectively generate a protective
immune response. Since BCG and MPL-SE have been
used for intradermal, subcutaneous or intramuscular
injection and may not be optimal for intraperitoneal
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routes could help in conclusive comparison of liposomes.
Further, since MPL is a potent inducer of Th1 response
and can function through subcutaneous route also, we
speculate that MPL can be combined with liposomes and
can be administered through subcutaneous route to over-
come the failure of liposomal vaccine through this route.
Indeed we have preliminary evidence showing that
immunization with liposomal antigens in association
with MPL-TDM can induce protection against L. dono-
vani infection in BALB/c mice through subcutaneous
route (unpublished observation). AS01, a liposomal for-
mulation containing MPL as a potent inducer of humoral
and cell-mediated response is already in clinical trials for
malaria [10]. Thus liposomal formulated MPL-
TDM+LAg may be the choice of adjuvant for vaccine
development against Leishmania and other intracellular
pathogens.
Conclusions
This comparative study of BCG+LAg and MPL-TDM +
LAg vaccines with cationic liposomal formulation of LAg
interestingly reveals a significantly greater effectiveness
of the liposomal vaccine for protection against progres-
sive VL in BALB/c. Evaluation of the immune responses
emphasize the need for an immunogenic vaccine for elic-
itation of potent vaccine-induced cellular immunity
based on both Th1 and Th2 cell responses to confer pro-
tection against the visceral disease. Thus, the cationic
liposomes offer a rational choice of adjuvant for the
development of vaccines against a range of infectious dis-
eases such as leishmaniasis, malaria and tuberculosis.
Methods
Animals
Female BALB/c mice (4-6 weeks old), bred in the animal
facility of Indian Institute of Chemical Biology (Kolkata),
were used for experimental purposes with approval of the
IICB Animal Ethical Committee and mice were handled
according to their guidelines.
Parasites and culture condition
L. donovani, strain AG83 (MHOM/IN/1983/AG83) was
originally isolated from an Indian kala-azar patient and
maintained in Syrian golden hamsters by serial passage as
described elsewhere [15]. Briefly, promastigotes were
grown at 22°C in Medium 199 (pH 7.4) supplemented
with 20% heat inactivated fetal bovine serum (FBS), 2
mM L-glutamine, 100 U/ml penicillin, 25 mM HEPES,
100 μg/ml streptomycin sulphate (all from Sigma-
Aldrich, St. Louis, USA), and the parasites were subcul-
tured in the same medium at an average density of 2 × 106
cells/ml at 22°C [15].
Preparation of leishmanial antigens
LAg was prepared from L. donovani promastigotes as
described earlier [15]. Briefly, stationary phase promas-
tigotes, harvested after the third or fourth passage in liq-
uid culture, were washed four times in cold 20 mM
phosphate-buffered saline (PBS), pH 7.2, and resus-
pended at a concentration of 1.0 g cell pellet in 50 ml of
cold 5 mM Tris-HCL buffer (pH 7.6). The suspension was
vortexed six times at 2 min each with a 10-min interval
on ice and centrifuged at 2,310 × g for 10 min. The crude
ghost membrane pellet thus obtained was resuspended in
the same Tris buffer and sonicated three times for 1 min
each at 4°C in an ultrasonicator (Misonix, New York,
USA). The suspension was finally centrifuged for 30 min
at 5,190 × g, and the supernatant containing leishmanial
antigens (LAg) was harvested and stored at -70°C until
used. The amount of protein obtained from a 1.0 g cell
pellet was approximately 14 mg, as assayed by the
method of Lowry et al. [49] with bovine serum albumin
as the standard, in the presence of 1% sodium dodecyl
sulphate and appropriate blanks.
Adjuvants
Positively charged liposomes were prepared with egg leci-
thin, cholesterol, and stearylamine (7:2:2 molar ratio),
respectively as reported earlier [15]. MPL (0.5 mg) plus
trehalose dicorynomycolate (TDM) (0.5 mg) in 2% oil
(squalene)-Tween 80-water was purchased from Sigma-
Aldrich Corp., St. Louis, USA. Briefly, each vial was
reconstituted with 1 ml saline and mixed at 1:1 ratio with
LAg in PBS and administered in mice as 50 μg/dose. The
mean particle size of the emulsion droplets was 128 ±
6.65 as determined by Zetasizer Nano-ZS (Malvern
Instruments, Worcestershire, UK). Bacillus Calmette
Guerin (BCG) (Pasteur Institute, Paris, France) was
diluted in PBS mixed at 1:1 ratio with LAg in PBS prior to
injection to an administrable dose of 5 × 104 cells/mice.
Entrapment of leishmanial antigens into cationic liposomes
For encapsulation of the LAg in the liposomal vesicles the
lipid film was dispersed in PBS containing 1 mg/ml LAg
and sonicated for 30 s in an ultrasonicator (Misonix) [15].
Liposomes with entrapped LAg were separated from
excess free materials by three successive washing in PBS
with ultracentrifugation (105,000 × g, 60 min, 4°C). The
mean size of the LAg entrapped liposomes was 337.3 ±
10.2 as determined by Zetasizer Nano-ZS (Malvern
Instruments). The presence of antigen could not influ-
enced the size of the vesicles (empty vesicles mean size
306.8 ± 2.6). The protein content entrapped into lipo-
somes was estimated by the method described by Lowry
et al. [49]. The phospholipid content of liposomes was
15.5 mg/ml as determined using the Stewart assay [50].
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ithin was 33 μg.
Vaccination and challenge infection
BALB/c mice were vaccinated by three intraperitoneal
injections of 20 μg of free LAg, incorporated in lipo-
somes, or associated with other adjuvants at 2-week
intervals in a total volume of 200 μl. PBS and only adju-
vant treated animals were included as controls. Ten days
after last immunization the animals were challenged
intravenously with 2 × 107 freshly transformed promas-
tigotes [15].
Evaluation of infection
At the times designated in Results, the course of infection
was evaluated by microscopic examination of Giemsa-
stainted impression smears of liver and spleen samples.
The organ parasite burden was expressed as Leishman-
Donovan units (LDU) calculated as follows: number of
amastigotes per 1,000-host cell nuclei × organ weight (in
mg) [51].
Antigen-specific antibody responses by ELISA
For determination of antibody responses, serum samples
collected from experimental groups of mice before and
after infection were analyzed for the presence of LAg-
specific immunoglobulin by ELISA. 96 well microtitra-
tion plates (maxisorp plates; Nunc, Roskilde, Denmark)
were coated with 100 μl of LAg (25 μg/ml) diluted in 20
mM phosphate buffer (pH 7.5) overnight at 4°C. Non-
specific binding sites were blocked with 1% bovine serum
albumin (BSA) in PBS at room temperature for 3 h. After
washing with PBS containing 0.05% Tween-20 (Sigma-
Aldrich), the plates were incubated overnight at 4°C with
1:1000 dilutions of mice sera. The plates were then
washed and incubated with horseradish peroxidase-con-
jugated goat anti-mouse IgG (Sigma-Aldrich) diluted
1:5000 and antimouse IgG1 or IgG2a (BD Pharmingen,
San Diego, USA) diluted 1:1000 in blocking buffer.
Finally, colour reaction was developed by the addition of
100 μl/well of substrate solution (o-phenylene diamine
dihydrochloride, 0.8 mg/ml in 0.05 M phosphate-citrate
buffer, pH 5.0, containing 0.04% H2O2) for 30 min. Absor-
bance was determined at 450 nm using ELISA plate
reader (Thermo, Waltham, USA) [15].
Delayed type hypersensitivity (DTH)
After the last vaccination, 2 and 4 months after challenge
infection, delayed-type hypersensitivity (DTH) was
determined as an index of cell-mediated immunity. The
response was evaluated by measuring the difference in
the footpad swelling at 24 h following intradermal inocu-
lation of the test footpad with 50 μl of LAg (800 μg/ml)
from that of control (PBS- injected) footpad with a con-
stant pressure caliper (Starret, Anthol, USA) [15].
Cytokine Assay
Spleens were removed aseptically from experimental
mice of each group at 10 days after last immunization and
teased between 20 μm pore size sieve into single cell sus-
pension in complete medium prepared with RPMI 1640
supplemented with 10% FBS, 10 mM NaHCO3, 10 mM
HEPES, 100 U/ml penicillin, 100 μg/ml streptomycin sul-
phate, and 50 μM β-mercaptoethanol (Sigma-Aldrich).
Erythrocytes were removed by lysis with 0.14 M Tris
buffered NH4Cl. The splenocytes were washed twice,
resuspended in culture medium and viable mononuclear
cell number was determined by Trypan blue exclusion.
Splenocytes were then cultured in a 96-well flat-bot-
tomed ELISA plate (Nunc) at a density of 2 × 105 cells/
well in a final volume of 200 μl. The cells were restimu-
lated in vitro with medium alone or with LAg (10 μg/ml)
and supernatants were collected after 72 h incubation at
37°C in a humified chamber containing 5% CO2 and
stored at -70°C until use. Measurements of IFN-γ and IL-
4 concentrations were carried out using Opt EIA Kits (BD
Pharmingen) as detailed in manufacturers' instructions
[27].
Statistical analysis
One-way ANOVA statistical test was performed to assess
the differences among various groups. Multiple compari-
sons Tukey-Kramer test was used to compare the means
of different experimental groups. A value of P < 0.05 was
considered to be significant.
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